

# Shilpa Lifesciences Private Limited

## Part - I - Balance Sheet

(All amounts are in Indian Rupees unless otherwise stated)

Particulars	Note	As at
		31.03.2022
		Audited
<b>ASSETS</b>		
<b>Non-Current Assets</b>		
a) Capital work- in- progress	2	550,487
b) Other non current assets	3	24,484,596
<b>Total Non Current Assets</b>		<b>25,035,083</b>
<b>Current Assets</b>		
a) Financial Assets :		
i) Cash and Cash equivalents	4	189,840
<b>Total Current Assets</b>		<b>189,840</b>
<b>TOTAL</b>		<b>25,224,923</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity:</b>		
a) Equity Share Capital	5	100,000
b) Other Equity	6	(15,115)
<b>Total Equity</b>		<b>84,885</b>
<b>Liabilities</b>		
<b>Non Current Liabilities</b>		
i) Borrowings	7	24,525,000
<b>Total Non Current Liabilities</b>		<b>24,525,000</b>
<b>Current Liabilities</b>		
a) Financial Liabilities		
i) Other financial liabilities	8	573,590
b) Other current liability	9	31,448
c) Provisions	10	10,000
<b>Total Current Liabilities</b>		<b>615,038</b>
<b>TOTAL</b>		<b>25,224,923</b>

The accompanying notes form an integral part of the financial statements 01 to 33

for BRAHMAVYA & CO.  
Chartered Accountants  
Firm Regn No. 0005135

For and on behalf of Board of Directors

**K.SHRAVAN**  
Partner  
Membership No. 215798

**Vishnukanth Bhutada**  
DIN No.01243391  
Director

**Ramakant Innani**  
DIN No.03222748  
Director

Place : Raichur  
Date : 30/04/2022

Place : Raichur  
Date : 30/04/2022

# Shilpa Lifesciences Private Limited

## Part - II - Statement of Profit and Loss

(All amounts in Indian Rupees except share data & per share data unless otherwise stated)

Particulars	Note	for the Period 31.03.2022
		Audited
<b>Revenue</b>		
Revenue from Operations		
Other Income		
<b>Total Revenue</b>		
<b>Expenses</b>		
a) Other Expenses	11	15,115
<b>Total Expenses</b>		<b>15,115</b>
<b>Profit / (Loss) before exceptional items and tax</b>		<b>(15,115)</b>
Exceptional (Income) / Expense		
<b>Profit / (Loss) before tax after exceptional Item</b>		<b>(15,115)</b>
<b>Tax expense</b>		
1. Current Income tax		
2. Deferred tax (Net)		
<b>Profit / (Loss) for the year</b>		<b>(15,115)</b>
<b>Other Comprehensive Income</b>		
<b>Total Comprehensive Income</b>		<b>(15,115)</b>
<b>Earning per equity share for Rs.10/- face value (Continued Operations)</b>		
Basic		(2.16)
Diluted		(2.16)
<b>Number of shares used in computing earnings per share (Continued Operations)(Weighted Average)</b>		
Basic		6,986
Diluted		6,986

The accompanying notes form an integral part of the financial statements 01 to 33

for BRAHMAVYA & CO.  
Chartered Accountants  
Firm Regn No. 0005135

For and on behalf of Board of Directors

K.SHRAVAN  
Partner  
Membership No. 215798  
Date : 30/04/2022

Vishnukanth Bhutada  
DIN No.01243391  
Director  
Date : 30/04/2022

Ramakant Innani  
DIN No.03222748  
Director

**Shilpa Lifesciences Private Limited**  
**Cash Flow Statement for the year ended March 31, 2022**  
(All amounts are in Indian Rupees unless otherwise stated)

Particulars	For the year ended 31.03.2022
<b><u>Cash Flows from Operating Activities</u></b>	
Profits Before Tax (PBT)	(15,115)
Gain on sale of Mutual Funds	-
<b>Operating profit before working capital changes &amp;</b>	<b>(15,115)</b>
<u>Adjustments for Increase / (Decrease) in Operating Liabilities</u>	
- Other Current Liabilities	31,448
- Short Term Provisions	10,000
- Other Financial Liabilities	573,590
<u>Adjustments for (Increase) / Decrease in Operating Receivables</u>	
	599,923
Less: Income Taxes (Net)	-
<b>Net Cash flow from Operating activities</b>	<b>599,923</b>
<b><u>CASH FLOWS FROM INVESTING ACTIVITIES</u></b>	
Purchase of Fixed Assets (Incl CWIP)	(550,487)
Advance for KIADB Land	(24,484,596)
Interest received	-
<b>Net cash used in Investing Activities</b>	<b>(25,035,083)</b>
<b><u>CASH FLOWS FROM FINANCING ACTIVITIES</u></b>	
Increase in Share Capital	100,000
Unsecured Loan	24,525,000
Interest paid	-
<b>Net Cash earned from Financing Activities</b>	<b>24,625,000</b>
<b>Net Increase/(decrease)in Cash and Cash Equivelants</b>	<b>189,840</b>
Cash & Cash Equivelants at the Beginning of the year	-
<b>Cash &amp; Cash Equivelants at the end of the year</b>	<b>189,840</b>

Components of Cash and Cash Equivalents	For the year ended 31.03.2022
Cash in Hand	-
Cash at Banks	189,840
<b>Total Cash and Cash Equivalents</b>	<b>189,840</b>

Note:

1.Cash Flow statement has been prepared under Indirect method as per Ind AS-7 "Statement of Cash flows" as prescribed under Companies (Accounting Standard) Rules, 2015.

for **BRAHMAVYA & CO.**  
Chartered Accountants  
Firm Regn No. 0005135

For and on behalf of Board of Directors

**K.SHRAVAN**  
Partner  
Membership No. 215798

**Vishnukanth Bhutada**  
DIN No.01243391  
Director

**Ramakant Innani**  
DIN No.03222748  
Director

Place : Raichur  
Date : 30/04/2022

Place : Raichur  
Date : 30/04/2022

# Shilpa Lifesciences Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

## 2 Capital work-in-progress

Particulars	As at 31.03.2022
a) Projects under erection	
b) Pre-operative Expenses -Rates & Taxes	236,011
c) Pre-operative Expenses -Interest on Loan	314,476
<b>TOTAL</b>	<b>550,487</b>

## 3 Capital work-in-progress

Particulars	As at 31.03.2022
a) Advance for Lease Hold land (KIADB)	24,484,596
<b>TOTAL</b>	<b>24,484,596</b>

## 4 Cash and Cash Equivalents

Particulars	As at 31.03.2022
a) Cash on hand	
b) Balance with banks in current account	189,840
<b>TOTAL</b>	<b>189,840</b>

## 6 Other Equity

Particulars	As at 31.03.2022
a) Retained Earnings	
Opening Balance	-
Add: Profit / (Loss) for the Period	<b>(15,115)</b>
<b>TOTAL</b>	<b>(15,115)</b>

## 7 Borrowings

Particulars	As at 31.03.2022
Unsecured Loan from Shilpa Medicare Ltd	24,525,000
<b>TOTAL</b>	<b>24,525,000</b>

## Shilpa Lifesciences Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

### 8 Financial Liabilities -Refer Note No -18

Particulars	As at 31.03.2022
Others Payable	290,562
Interest accrued but not due on borrowings	283,028
<b>TOTAL</b>	<b>573,590</b>

### 9 Other Current Liabilities

Particulars	As at 31.03.2022
1) Tax deduction at source	31,448
<b>TOTAL</b>	<b>31,448</b>

### 10 Provision

Particulars	As at 31.03.2022
a) Provision For Audit Fee	10,000
<b>TOTAL</b>	<b>10,000</b>

### 11 Other Expenses

Particulars	As at 31.03.2022
a) Bank Charges	564
b) Rates & Taxes -Roc Filing Fees	4,551
c) Payment to Auditors (Refer Note No.12)	10,000
<b>TOTAL</b>	<b>15,115</b>

### 12 Payment to Statutory Auditors \*

Particulars	As at 31.03.2022
a) Statutory Audit	10,000
	-
	-
<b>TOTAL</b>	<b>10,000</b>

**Shilpa Lifesciences Private Limited**

**13 Financial Ratios**

Sl No	Particular	Numerator	Denominator	31st March 2022	Variation %	Reasons for variance of above 25%
1	Current Ratio(in times)	Current Assets	Current Liabilities	0.31	100.00%	Variance is primarily on account of mainly increase in payables due to Interest Payable & ROC pre Incorporation Expenses
2	Debt Equity Ratio(in times)	Total Debt	Share holder equity	288.92	100.00%	Variance is on account of loan borrowed during the year from Shilpa Medicare Ltd.
3	Return on equity(in %)	Net profit after taxes	Average shareholders equity	-17.81%	100.00%	Variance is primarily on account of other equity for FY 21-22 considered only for 1 year
4	Return on Capital Employed(%)	Earning Before Interest and Tax	Capital Employed	-0.06%	100.00%	Variance is primarily on account of increase in the capital borrowed during the year.

## Shilpa Lifesciences Private Limited

(All amounts are in Indian Rupees unless otherwise stated)

### 5 Equity Share Capital

#### A. Equity Share Capital

Particulars	As at
	31.03.2022
<b>Authorised</b>	
<b>Equity shares</b>	
100,000 Shares of Rs. 10/- each par value	1,000,000
<b>TOTAL</b>	<b>1,000,000</b>

#### a) Reconciliation of the number of shares.

Particulars	31.03.2022	31.03.2022
	No.	Amount
Shares outstanding at the beginning of the year		
Shares Issued during the year	10,000	100,000
<b>Shares outstanding at the end of the year</b>	<b>10,000</b>	<b>100,000</b>

#### c) Shareholders holding more than 5% shares in the Company

Particulars	31.03.2022	31.03.2022
	% of Holding	% of Holding
1) Shilpa Medicare Ltd		
2) Shilpa Pharma Lifesciences Limited (Formerly Known as Shilpa Corporate Holdings Pvt Ltd	99.99%	99.99%

#### **Note:**

01 share is held by Ramakant Innani in the representative capacity on behalf of Shilpa Medicare Ltd. (Holding Co)

Shares held by promoters at the end of the year

Particulars	31.03.2022	
	No of Shares	% of Change during the year***
1) Shilpa Pharma Lifesciences Limited	9999	100%

## Shilpa Lifesciences Private Limited

### 5 A) Equity Share Capital

Particulars	Equity Share capital - 31.03.2022
<b>Balance at the beginning of the Reporting period</b>	-
Changes in Equity Share Capital due to prior period errors	-
Restated balance at the beginning of the current reporting period	
Changes in equity share capital during the current year	<b>100,000</b>
<b>Balance at the end of the reporting period</b>	<b>100,000</b>

### 5 B) Other Equity

Particulars	Share application money pending allotment	Equity component of compound financial instruments	Reserves and Surplus	Reserves and Surplus		Items of other comprehensive income	For the Period 31.03.2022
			Retained Earnings	Exchange difference on translating the financial statement of foreign operation	OCI Gain on forfeiter of equity shares	Actuarial Gain / (Loss)	
Balance at the beginning of the current reporting period	-	-	-	-	-	-	-
Changes during the period	-	-	-	-	-	-	-
Restated balance at the beginning of the reporting period	-	-	-	-	-	-	-
Total Comprehensive income for the year	-	-	-	-	-	-	(15,115)
Dividends	-	-	-	-	-	-	
Transfer to retained earning	-	-	-	-	-	-	
Any other change ( to be specified)	-	-	-	-	-	-	
<b>Balance at the end of the reporting period</b>	-	-	-	-	-	-	<b>(15,115)</b>



## 14 Related Party Transactions

Related parties where control exists and related parties with whom transactions have taken place during the period 01 April 2021 to 31 March 2022 are listed below:

### 1 Holding Company

a) Shilpa Medicare Limited - Holding Company

				2021-22	
SL No	Name of related Party	Relationship	Descriptions of Transaction	Income/(expense) other transaction	Balance at 31.03.2022
a)	<b>Enterprises having common Directors</b>				
i	Shilpa Medicare Limited	Holding Company	Reimbursement of Expenses Unsecured Loan Interest on Loan	(290,562) (24,525,000) (283,028)	(290,562)  (24,241,972)